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Abstract 
Inhibitor of apoptosis proteins (IAPs) regulate the activity of caspases in apoptosis.  The 
human X chromosome-encoded IAP (XIAP) is one of the more potent members of the 
IAP family and it has been described as a central regulator of apoptosis.  Thus, 
molecules that inhibit XIAP could offer therapeutic opportunities to treat unwanted 
apoptosis inhibition.  In the present study we have applied the SOSA (selective 
optimization of side activities) approach to the discovery of XIAP inhibitors.  In this 
sense, we have identified Dequalinium Hydrochloride (Dq) as an inhibitor of the 
XIAP/caspase-3 interaction both in vitro and in cellular assays. 
Introduction 
Inhibitor of apoptosis proteins (IAPs) regulate or control the activity of both effector 
and initiator caspases.  IAPs were initially identified in baculovirus as proteins that 
enhance virus infectivity by inhibition of host cell apoptosis (1).  The mammalian 
family of IAPs is comprised of 8 different members with different functions.  Cellular 
IAP1 (cIAP1), cellular IAP2 (cIAP2) and human X chromosome-encoded IAP (XIAP) 
are implicated in regulation of apoptosis.  XIAP is one of the more potent members of 
the IAP family and it has been described as a central regulator of apoptosis (2, 3).  In 
addition to its role as caspase inhibitor, recent evidences suggest that XIAP directly 
participates in NF- and MAP kinase activation (4).  XIAP contains two types of 
conserved sequence motifs; the baculovirus IAP repeats (BIRs) and the zinc finger-like 
RING.  It has been shown that recombinant XIAP is able to specifically block the 
activity of caspases-3, -7, and -9 (5, 6).  The spacer region between BIR1 and BIR2 
domains interacts with caspases-3 and -7 while BIR3 targets caspase-9 (7-9).  As XIAP 
regulates caspase activation, the Smac/DIABLO protein (second mitochondria-derived 
activator of caspases/direct IAP-binding protein with low PI) inhibits XIAP when 
released from mitochondria upon activation of apoptosis. 
When malignant cancer cells fail to activate apoptosis increase their survival factors.  
Thus, molecules that inhibit IAPs could offer therapeutic opportunities to treat 
unwanted apoptosis inhibition.  As reviewed by Schimmer et al. (10) two approaches 
have been explored in developing XIAP inhibitors:  antisense oligonucleotides and 
small molecule inhibitors.  In the latter approach both rational design and screening of 
compounds have provided interesting XIAP inhibitors.  The rational design approaches 
have been directed to mimic the Smac/DIABLO-XIAP interaction that is based in the 
targeting of both BIR2 and BIR3 domains in XIAP by the AVPI tetrapeptide motif 
found in Smac/DIABLO (11, 12).  Small-molecule XIAP inhibitors were reported from 
successful screening campaigns of a 160,000 small-molecule library by Wu et al. (13) 
and of approximately 1 million, including peptidyl and non-peptidyl, compound library 
by Schimmer et al. (14).  However, the SOSA (selective optimization of side activities) 
(15) approach has not been applied to the discovery of XIAP inhibitors.  The SOSA 
approach consists of testing “old” drugs on new pharmacological targets.  The aim is to 
subject to screening a limited number of drug molecules that are structurally and 
therapeutically very diverse and that have known safety and bioavailability in humans.  
In this sense, we have screened the Prestwick Chemical Library® and identified 
Dequalinium Hydrochloride (Dq) as an inhibitor of the XIAP/caspase-3 interaction both 
in vitro and in cellular assays. 
Materials and methods 
Materials.  The Prestwick Chemical Library® was purchased from Prestwick Chemical 
(www.prestwickchemical.com).  A synthetic peptide including the first seven N-
terminal residues of Smac (AVPIAQK - pSmac) was synthesized by Fmoc chemistry, 
characterized by mass spectrometry and purified by HPLC.  MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide), Dequalinium Chloride, 
Glafenine Hydrochloride, Benzetonium Chloride and Methyl Benzethonium were 
purchased from Sigma.  Ac-DEVD-afc and z-DEVD-CHO were from Biomol and 
Calbiochem, respectively.  Tumour necrosis factor  (TNF) was from PeproTech.  
HeLa cell line was obtained from the American Type Culture Collection (ATCC).  
XIAP antibody (#2042) was from Cell Signalling. 
Cell cultures and HeLa cell extracts.  Cell cultures were grown at 37 ºC in DMEM 
medium in the presence of 10% fetal bovine serum under atmosphere of 5% CO2.  Cells 
were seeded in 15 cm plates at 1-2 x 106 cells per plate and harvested when confluent 
(approximately 107 cells per plate).  S-100 extracts from HeLa cells (16) were prepared 
from 2 x 108 cells in 50 mM PIPES pH 7, 50 mM KCl, 5 mM EGTA, 2 mM MgCl2, 1 
mM DTT.  Caspase-3 was activated by addition of 10 mM dATP and 10 M 
Cytochrome c to the cellular extract. 
Caspase-3 de-repression assay.  Caspase-3 de-repression assay was assessed as 
previously described (13).  Briefly, the active form of caspase-3 was reconstituted from 
its constituent subunits (17).  The assay was performed in 96-well plate format.  
Recombinant GST-XIAP (XIAP) in caspase buffer (50 mM HEPES, pH 7.4, 100 mM 
NaCl, 10% sucrose, 1 mM EDTA, 0.1% CHAPS) was preincubated for 15 minutes at 
room temperature with the library compounds at the indicated concentrations and then 
recombinant caspase-3 was added.  As a control of de-repression the pSmac peptide was 
used.  Caspase-3 activity was continuously monitored following the release of 
fluorescent afc from the caspase-3 substrate Ac-DEVD-afc, at 30 ºC using a Victor 2 
spectrofluorimeter (Perkin Elmer - exc= 390 nm; em= 510 nm).  
Caspase-9 de-repression assay.  Procaspase-9 in pET23b was transformed in E. coli 
BL21(DE3) and cells were grown to OD 0.6.  Expression was induced with 0.2 mM de 
IPTG for 3 hours at 30 ºC.  Cells were then lysed by sonication and protein purified by 
affinity in a His Trap HP column.  The eluted protein was further purified by ionic 
exchange in a Hi Trap Q HP column in 20 mM Tris pH 8.5, 5% glycerol, 1 mM DTT 
buffer with a gradient of NaCl.  For the de-repression assay 100 nM of procaspase-9 
was previously pre-activated in SC buffer (50 mM Na2HPO4, 150 mM NaCl, 1.5% 
Sucrose, 0.05% CHAPS, 0.7 M Sodium Citrate pH 7.4) and then the complete reaction 
was developed in S buffer (50 mM Na2HPO4, 150 mM NaCl, 1.5% Sucrose, 10 mM 
DTT, 0.35 M Sodium Citrate, pH 7.4).  Activated caspase-9 (100 nM) was then used in 
the de-repression assay following the procedure described for the de-repression assay of 
caspase-3 but in the presence of the caspase-9 specific substrate Ac-LEHD-afc at 25 ºC. 
Caspase-3 and caspase-9 activity assays.  The enzymes were incubated in the 
presence (15 min) or absence of a defined concentration of the compounds to test in 
caspase buffer and then Ac-DEVD-afc or Ac-LEHD-afc, substrates for caspase-3 or 
caspase-9, respectively, were added.  Enzyme activity was monitored following the 
release of fluorescent afc at 30 ºC using a Victor 2 spectrofluorimeter (exc= 390 nm; 
em= 510 nm). 
NMR experiments.  All spectra were recorded at 298 K with a Bruker Ultrashield Plus 
Avance II 600 MHz spectrometer equipped with a 5 mm cryogenically cooled TCI 
probe.  An NMR sample consisted of 1 M XIAP and 20 or 100 M Dq from a 50 mM 
stock in DMSO-d6, at protein:ligand ratios of 1:20 and 1:100 for the water-LOGSY and 
STD experiments, respectively.  The sample buffer was 50 mM phosphate pH 7.0 with 
50 mM NaCl.  8 K points were used for a sweep width of 9,600 Hz and a total of 256 
scans were accumulated for the water-LOGSY and STD experiments.  In the water-
LOGSY experiments, the large bulk water magnetization is partially transferred via the 
protein-ligand complex to the free ligand in a selective manner.  A non interacting 
compound results in negative resonances, whereas protein-ligand interactions are 
characterized by positive signals or by a reduction in the negative signals obtained in 
the absence of the protein.  In the STD experiment, a positive interaction is recognized 
by the presence of positive signals, a negative interaction yielding no signals. 
Silencing of XIAP.  HeLa cells were seeded in 24-well plates at a cell density of 40000 
cells/mL and transfected with either 100 nM XIAP siRNA or random siRNA (Cell 
Signaling) using LipofectAMINE2000 (Invitrogen) according to manufacturer´s 
instructions.  24h post-transfection cells were treated with the indicated concentrations 
of Dq and left to grow for additional 24h.  Cell viability was determined by MTT. 
Caspase activation assays in cellular models.  Cell extracts were prepared from HeLa 
cells seeded in 3.5 cm plates at 3x105 cells per plate.  After treatments, cells were 
harvested, the pellets were resuspended in 30 L of extraction buffer (50 mM PIPES, 50 
mM KCl, 5 mM EDTA, 2 mM MgCl2, 2 mM DTT supplemented with protease 
inhibitor cocktail from Sigma) and kept on ice 5 min.  After 3 rounds of freeze and 
thaw, cell lysates were centrifuged at 14000 rpm 5 min and supernatants were collected.  
Quantification of total protein concentration from these cell extracts was performed 
using the bicinchoninic acid method (Pierce).  Aliquots with appropriate protein content 
were mixed with 200 µL of caspases assay buffer (PBS, 10% glycerol, 0.1 mM EDTA, 
2 mM DTT) containing 20 µM of Ac-DEVD-afc.  Caspase activity was continuously 
monitored following the release of fluorescent afc at 30 ºC using a Victor 2 
spectrofluorimeter (exc= 390 nm; em= 510 nm).  DEVDase activity was expressed as 
either an increase of relative fluorescence units per min (∆FU/min) or as percentage of 
the initial fluorescence signal value. 
Results and Discussion 
Identification of Dequalinium as inhibitor of XIAP 
For the screening we employed an enzymatic de-repression assay (14) based on the 
XIAP-mediated inhibition on active caspase-3.  The objective is to screen the library to 
identify compounds that relieve XIAP inhibition, allowing caspase-3 to cleave a 
fluorogenic substrate (see Materials and methods).  From the screening and dose-
response experiments we identified four compounds (Table I – Fig. 1A) as potential 
XIAP inhibitors with IC50 (compound concentration that provides 50% inhibition of the 
XIAP/caspase complex) values similar to the polyphenylureas described by Schimmer 
et al. (14).  Dequalinium Hydrochloride (Dq – chemical structure in top panel of Fig. 2) 
was the most promising hit with an IC50 of 34 M against full-length XIAP (Fig. 1B).  
None of the hit-compounds identified had a direct activation effect on the enzymatic 
activity of caspase-3 (Fig. 1A) therefore the increase in activity obtained in the 
biological assay must be a consequence of a hit compound-mediated inhibition of the 
XIAP/caspase-3 complex.  Furthermore, Dq and Glafenine Hydrochloride (Gfa) were 
not able to de-repress XIAP-inhibited caspase-9 (Fig. 1C, D) or to induce a direct 
inhibition on caspase-9 activity while we observed that Benzethonium Chloride (Bz) 
and Methyl Benzethonium (MBz) inhibited the enzymatic activity of caspase-9 (Fig. 
1C). 
Dequalinium binds to XIAP as characterized by nuclear magnetic resonance 
The interaction between Dq and XIAP was further analyzed by nuclear magnetic 
resonance spectroscopy (NMR).  We used two complementary ligand-based NMR 
techniques covering a wide range of binding affinities: water-LOGSY (water-Ligand 
Observed by Gradient SpectroscopY) (18); and STD (Saturation Transfer Difference) 
(19).  Both experiments are ligand-based, i.e. the analysis is focused on the effects 
caused on the ligand NMR signals upon binding to the target.  An excess of ligand is 
mixed with the target protein, and the exchange between the bound and free states of the 
ligand originates the effects observed on the latter.  In the case of the STD experiment 
two spectra are recorded, one saturating all the protons of the protein and a second 
without saturation.  Any ligand bound to the target protein will also be saturated in the 
first experiment, and this saturation will be transferred via exchange to the ligand in the 
free form.  The difference between both spectra will yield only the signals from the 
binding ligand, as a non-binding ligand will produce the same spectrum with and 
without saturation and therefore its signals will cancel out.  The water-LOGSY 
experiment makes use of the water molecules bound at the target-ligand interface to 
transfer selectively the magnetization from the complex to the free ligand.  A positive 
interaction between a ligand and a target protein is characterised by a positive signal in 
the 1D 1H spectrum or by a reduction in the negative signal in the reference spectrum 
(experiment recorded in the absence of the target protein).  In our experiments, 1 M 
XIAP was incubated with Dq at a 1:20 (protein:ligand) excess in the water-LOGSY 
experiment and at a 1:100 excess in the STD experiment.  Figure 2a shows the 1D 1H 
spectrum of XIAP and Dq with the signals from the molecule identified.  The unmarked 
resonances belong to other protonated chemicals present in the buffer.  The water-
LOGSY experiment (Fig. 2b) shows opposite sign for the resonances contributed by Dq 
(positive) and the non-binding chemicals present in the sample (negative), indicating 
that binding occurs between XIAP and Dq.  A control water-LOGSY recorded in the 
absence of XIAP rendered negative signals for Dq (not shown).  The XIAP-Dq binding 
was further confirmed by the STD experiment (Fig. 2c) which yielded positive signals 
for those resonances arising from Dq, while the non-binding compounds did not show 
any signals in the spectrum.  As XIAP is expressed and purified using a GST protein 
fusion as a tag (see Materials and methods), the same experiments were repeated for 
GST and Dq (Fig. 2 d,e) and no interaction was found, thus confirming that Dq binds to 
XIAP. 
Dequalinium inhibits XIAP in cells extracts and in cell cultures 
The in vitro results suggested that Dq could be a potential hit as selective inhibitor of 
the XIAP/caspase-3 interaction.  However in a cellular milieu, in vitro active molecules 
have to deal with a number of possible interactions that could compromise their activity 
on the molecular target.  To further explore the efficacy of these hits in a cellular 
environment, their activity was initially evaluated in mammalian cellular extracts.  
Cytosolic extracts from human epithelial carcinoma cell line (HeLa) were activated to 
enter the apoptotic pathway by incubation with ATP and Cytochrome c (Cyt c) (16) that 
induces caspase-3 activity.  We found that concentrations between 0.1 and 0.5 nM of 
exogenous recombinant XIAP were needed to induce close to 50% inhibition of 
cytosolic extract caspase-3 activity (Fig. 3A).  In these experimental conditions Dq was 
able to de-repress XIAP-induced caspase-3 activity in the cell extracts (Fig. 3B). 
Dq is a cation delocalized lipidic drug that has been described to accumulate in 
mitochondria due to the high mitochondrial membrane potential (20) inducing cell death 
in different cell lines.  However, the molecular mechanism behind cell death induction 
is still unclear and different pathways have been postulated to be affected by Dq (20-
22).  In this study we have discovered that Dq, in vitro and in cell extracts, targets the 
complex XIAP/caspase-3 which seems to indicate that apoptosis induction could be at 
the basis of the molecular mechanism of action of Dq.  In fact, when HeLa cells were 
treated with different concentrations of Dq we obtained cell death induction (Fig. 4) and 
caspase-3 activation (Inset Fig. 4).  Western blot analysis demonstrates that Dq does not 
affect the cellular levels of XIAP (Fig. 4).  Furthermore, siRNA-mediated depletion of 
XIAP drastically reduced HeLa cell sensitivity to Dq-induced cell death (Fig. 5A).  It 
has been demonstrated that previously discovered small molecule inhibitors of XIAP 
synergize with tumor necrosis factor alpha (TNF) to induce both, caspase activation and 
apoptosis in human cancer cells (12) as well as tumor regression in xenograft mouse 
models (23).  In the same line of evidence Dq-induced cell death was enhanced in the 
presence of sublethal concentrations of TNF, reinforcing the role of XIAP as cellular 
target of Dq (Fig. 5B). 
Concluding remarks 
In the present study we have shown that Dq binds to XIAP and inhibits the complex 
XIAP/caspase-3 (but not XIAP/caspase-9), induces apoptotic cell death and also is able 
to potentiate the pro-apoptotic activity of TNF.  Dq is a classic bacteriostatic indicated 
for the use in mouth, skin and vaginal infections having also cytostatic activity in 
tumour cells (20, 22, 24).  It was also shown that Dq was able to induce size reduction 
in rat colon tumour isografts (25).  Dq accumulates preferentially in mitochondria of 
cancer cell lines (26).  Protein kinase C has also been postulated as one of the potential 
targets (21) of Dq but the ultimate molecular mechanism of cell death induction has not 
been solved.  Here we show that Dq is able to de-repress XIAP-mediated caspase-3 
enzyme activity thereby re-establishing the progression of the apoptotic program in 
tumour cells.  Taking into account the preferential accumulation of the drug into the 
mitochondria it can be postulated a mechanism of action for Dq similar to that of the 
natural inhibitors of XIAPs.  Dq preferentially accumulates in the mitochondria of Dq-
treated tumour cells, probably due to the different mitochondrial potential, and could be 
released after cell death induction.  Accumulative interaction of Dq within 
mithochondrial membranes could induce mitochondrial leakage which produces 
liberation of the drug to the cytosol and amplification of the cell death-signal by 
inhibition of XIAP-caspase-3 interaction.  Recently, it has been shown that XIAP 
accumulates in the mitochondrial membrane shortly after cell death induction and 
promotes the formation of a complex that helps mitochondrial transition to permeability 
leading to Cyt c and Smac/DIABLO release (27).  Therefore it is plausible an initial 
interaction between Dq and XIAP at the mitochondrial level that could compromise the 
anti-apoptotic activity of XIAP. 
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Legends to Figures 
Figure 1.  The compounds identified as XIAP inhibitors hits (Dq, Bz, MBz and Gfa), 
de-repress caspase-3- but not caspase-9-XIAP mediated inhibition.  Measure of caspase-
3 (A, B) and caspase-9 (C, D) activity in the presence or absence of XIAP (100 nM and 
400 nM, in panels A and C, respectively) and of Dq, Bz, MBz and Gfa at 50 M (A, C).  
The activity of the enzyme in the absence of XIAP or compounds (C+) was defined as 
100%.  In the presence of XIAP the enzyme activity is inhibited and, as a control, we 
used a synthetic peptide derived from the natural XIAP-inhibitor Smac/Diablo (pSmac 
at 1 mM - see Material and methods section) that de-repressed the XIAP-inhibited 
enzyme activity.  Dq, Bz, MBz and Gfa were able to de-repress XIAP-inhibited 
caspase-3 (panel A) but not XIAP-inhibited caspase-9 (panel C).  All four hits did not 
have any effect on caspase-3 activity in the absence of XIAP (panel A) but Bz, MBz 
and Gfa exerted an inhibitory effect on caspase-9 (panel C).  Panels B and D are Dq full 
dose-response curves for de-repression of caspase-3 and -9 activities, respectively.  In 
these panels the percentages of enzyme activity with respect to the value obtained in the 
XIAP-inhibited control are plotted.  Data represent the means ± s.d. of three 
independent experiments. 
Figure 2.  Chemical structure of Dq and detail of the aromatic (left) and aliphatic (right) 
regions of the NMR binding experiments of XIAP with Dq.  (a) 1D 1H NMR of the 
mixture XIAP-Dq; the Dq resonances are labelled according to the chemical structure; 
the unmarked signals belong to other chemicals present in the protein buffer.  XIAP-Dq 
water-LOGSY (b) and STD (c) experiments show positive signals arising from Dq, thus 
proving the interaction between the protein and the molecule.  The same experiments 
were repeated for control GST and Dq (d-e; see main text).  All spectra were recorded at 
298 K. 
Figure 3.  Activity of the compounds identified as XIAP inhibitors hits (Dq, Bz, MBz 
and Gfa), in HeLa cellular extracts.  (A) Measure of caspase-3 percentage of inhibition 
when ATP- and Cyt c-activated HeLa cellular extracts were incubated in the presence of 
increasing concentrations of XIAP.  As control of the assay the same extracts were 
incubated in the presence (DEVD inh) or absence (Ctrl) of 100 nM of the irreversible 
caspase-3 inhibitor Ac-DEVD-CHO.  (B) ATP- Cyt c-activated HeLa cellular extracts 
in the presence of 0.1 nM of XIAP were pre-incubated (15 min) in the presence  or 
absence (-) of the different compounds (50 M) and the recovery of caspase-3 activity 
respect the XIAP inhibited sample was evaluated.  Data represent the means ± s.d. of 
three independent experiments. 
Figure 4.  Dq induces cell death by apoptosis in HeLa cell cultures without affecting 
the protein levels of XIAP.  HeLa cells were incubated with increasing concentrations 
of Dq for a period of 24 hours.  Cell viability was determined by MTT and XIAP 
protein expression by western blot.  Caspase-3 activation in the presence of Dq 25M 
was determined (Figure inset).  Data represent the means ± s.d. of three experiments. 
Figure 5.  Dq activity is influenced by the presence of XIAP in the cell and synergizes 
with TNF. (A) Silencing of XIAP diminishes cell death induced by Dq.  HeLa cells 
were transfected with either XIAP or a random siRNA (see Materials and methods) and 
incubated for 24h.  Dq (5 M) was then added to the media and cells were incubated for 
an additional period of 24h.  Cell viability was measured by MTT.  (B) Treatment with 
Dq sensitizes cells to death induced by TNF.  HeLa cells seeded in 96 well plates (4000 
cell/well) were treated with 50 M Dq for 4 hours, then TNF 50 ng/mL was added to 
the media and cells were incubated for additional period of 20 hours.  Cell viability was 
measured by MTT.  Data represent the means ± s.d. of three experiments (*p<0.05). 
 
Table I.  Compound concentration that provides 50% inhibition (IC50) for the 
XIAP/caspase-3 complex identified from the library screening.   
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